Observational studyIrish journal of medical science2022
COVID-19 infection is a major cause of acute telogen effluvium.
Observational study in Irish journal of medical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 72 citations in OpenAlex.
- Post-COVID Hair Loss in the Indian Subcontinent: Clinical Patterns and Association with Disease Severity.Dermatology practical & conceptual · 2025Article
- Recovery Effects of Oral Supplementation with Polar Lipid-Rich Wheat Extracts on Acute Telogen Effluvium: A Randomized Double-Blind Placebo-Controlled Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Incidence of alopecia and hair loss among female active component service members, 2010-2022.MSMR · 2024Article
- Comparison of Telogen Effluvium Incidence in Hospitalized and Outpatient Settings after Recovery from COVID-19.Iranian journal of medical sciences · 2024Article
- COVID-19-induced hair shedding and related risk factors: A Saudi perspective.Journal of family medicine and primary care · 2023Article
- A Cross-Sectional Study on Post-Coronavirus Disease (COVID-19) Hair Loss at a Tertiary Care Hospital.Dermatology practical & conceptual · 2023Article
- [Review of the post-COVID-19 syndrome associated to acute telogen effluvium].Revista medica del Instituto Mexicano del Seguro Social · 2023Review
- Long- COVID and general health status in hospitalized COVID-19 survivors.Scientific reports · 2023Article
- A Systematic Review and Quality Evaluation of Studies on Long-Term Sequelae of COVID-19.Healthcare (Basel, Switzerland) · 2022Review
- On the Potential Role of the Antioxidant Couple Vitamin E/Selenium Taken by the Oral Route in Skin and Hair Health.Antioxidants (Basel, Switzerland) · 2022Review
- Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia.Journal of family medicine and primary care · 2022Article
- Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management.The Journal of dermatology · 2022Review
- Article
- Article
- Characteristics of hair loss after COVID-19: A systematic scoping review.Journal of cosmetic dermatology · 2022Article
- Hair Loss and Telogen Effluvium Related to COVID-19: The Potential Implication of Adipose-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma as Regenerative Strategies.International journal of molecular sciences · 2022Review
- The Impact of COVID-19 Pandemic on Dermatological Conditions: A Novel, Comprehensive Review.Dermatopathology (Basel, Switzerland) · 2022Review
- Alopecia in patients with COVID-19: A systematic review and meta-analysis.JAAD international · 2022Review
- Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity.Journal of medicine and life · 2022Observational
- Evaluation of patients with telogen effluvium during the pandemic: May the monocytes be responsible for post COVID-19 telogen effluvium?Journal of cosmetic dermatology · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute telogen effluvium is a non-scaring hair loss, usually occurs 3 months after the stressful event that causes hair shedding, and lasts up to 6 months. It can be associated with post COVID-19 infection.
objectiveTo study the possible effects of COVID-19 on the hair growth cycle and the relationship between COVID-19 and acute telogen effluvium. PATIENTS AND
methodsThis is an observational cross-sectional study that had been conducted during the period from September 2020 to March 2021 years. Thirty-nine patients with post COVID-19 hair loss are confirmed by polymerase chain reaction (PCR) or antibody testing. Hair pull test was carried out to confirm the diagnosis and severity of telogen effluvium.
resultsThirty-nine patients were evaluated; their ages ranged from 22 to 67 years with a mean and SD of 41.3 ± 11.6 years with 36 (92.3%) females and 3 (7.69%) males. All patients with a diagnosis of ATE were enrolled in this study and had a laboratory-confirmed diagnosis of prior SARS-CoV-2 infection; 15 (38.46%) patients reported mild symptoms, 24 (61.53%) patients presented with moderate disease, and no patient required hospitalization. They all experienced excessive hair loss within 2-3 months after infection. Pull tests were strongly positive (> 10-50% with a mean of 35% of pulled hair away from scalp).
conclusionCOVID-19 infection is now a frequent and a common cause of acute telogen effluvium. Hence, clinicians should be aware about the relation between this infection and this pattern of hair loss. Drugs that have been used for the treatment of COVID-19 were excluded as a cause of acute telogen effluvium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.